Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.77 |
| ▸ | CA12 | O43570 | 5/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | LTK | P29376 | 1/20 | 0.56 |
| ▸ | GRK5 | P34947 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | PRKX | P51817 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834865 | 1.00 | CA9 (0.77) | CA9CA12CHEK1DAPK3MAP4K4 | |
| SCHEMBL1957257 | 0.87 | CA12 (1.00) | CA9CA12CHEK1DAPK3MAP4K4 | |
| SCHEMBL29876943 | 0.87 | CA12 (1.00) | CA9CA12CHEK1DAPK3MAP4K4 | |
| SCHEMBL9302358 | 0.73 | CA9 (0.54) | CA9CA12CYP3A4TDP1CAPN9 | |
| SCHEMBL8879523 | 0.72 | KMT2A (0.62) | CA9CA12LRRK2CYP3A4TDP1 | |
| SCHEMBL3988311 | 0.72 | CA12 (0.73) | CA9CA12CHEK1DAPK3MAP4K4 | |
| SCHEMBL1684375 | 0.72 | CHEK1 (0.62) | CA9CA12CHEK1DAPK3MAP4K4 | |
| SCHEMBL32689426 | 0.72 | CHEK1 (0.62) | CA9CA12CHEK1DAPK3MAP4K4 | |
| SCHEMBL3984666 | 0.72 | RET (1.00) | CA9CA12CHEK1DAPK3MAP4K4 | |
| SCHEMBL2208975 | 0.72 | CHEK1 (0.62) | CA9CA12CHEK1DAPK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4323066-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117580835-A | MEK inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2022221866-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| CN-111499592-A | Synthesis method of 5-aminomethyl saccharin | 江苏省农用激素工程技术研究中心有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | INVENTIVA (FR) | 2020-04-16 | — | — | US | disclosed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| EP-2513229-B1 | DISPERSE AZO DYES, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2513229-A1 | DISPERSE AZO DYES, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF | Huntsman Advanced Materials (Switzerland) GmbH (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20060100103-A1 | Toning agents for use in thermographic recording materials | AGFA-GEVAERT (BE) | 2006-05-11 | — | — | US | disclosed |
| EP-0646112-A4 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS. | ABBOTT LAB (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0646112-A1 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-04-05 | — | — | EP | disclosed |
| US-5288749-A | Treating central nervous system or cardiovascular disorders | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1993012754-A2 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4258129-A | IMPROVE GREEN SHELF LIFE | FUJI PHOTO FILM CO., LTD. (JP) | 1981-03-24 | — | — | US | disclosed |
| US-4211839-A | SILVER HALIDE AND ORGANIC SILVER SALT PREPARED IN AN IMINO COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-08 | — | — | US | disclosed |
| US-4144072-A | CONTAINING A PHTHALAZINONE AND A PHTHALIMIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1979-03-13 | — | — | US | disclosed |
| US-4125403-A | ORGANIC SILVER SALT, SILVER HALIDE, REDUCING AGENT, PHTHALAZINONE, AND A BENZOXAZINEDIONE OR QUINAZOLINEDIONE | FUJI PHOTO FILM CO., LTD. | 1978-11-14 | — | — | US | disclosed |
| US-4057555-A | FROM PHOSGENE AND O-SULFOBENZOIC ACID, DIMETHYLFORMAMIDE, ALCOHOL, AMMONIA | IHARA CHEMICAL INDUSTRY CO., LTD. (JA) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | YAP1, TEAD2, TEAD1 | CA9 2285/4885CA12 4126/4885CHEK1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.